The effects of rofecoxib, a cyclooxygenase (COX)-2 specific inhibitor, vs ibuprofen on biochemical indices of bone turnover in patients with osteoarthritis.

被引：0

|

作者：

Murphy, MG

Kivitz, AJ

Palmer, M

Zeng, Q

Bolognese, J

Gertz, BJ

机构：

[1] Merck Res Labs, Rahway, NJ USA

[2] Altoona Ctr Clin Res, Altoona, PA USA

来源：

JOURNAL OF BONE AND MINERAL RESEARCH | 1999年 / 14卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

SA133

引用

收藏

页码：S342 / S342

页数：1

相关论文

共 33 条

[31] Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis
Eisen, GM
Goldstein, JL
Hanna, DB
Rublee, DA
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (05) : 591 - 598
[32] The effects of cyclooxygenase-2 [COX-2] inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus (vol 165, pg 161, 2005)
Sowers, JR
White, WB
Pitt, B
Whelton, A
Sinion, LC
Winer, N
Kivitz, A
van Ingen, H
Brabant, T
Fort, JG
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (05) : 551 - 551
[33] Effects of radium-223 dichloride (Ra-223) with docetaxel (D) vs D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): A phase 1/2a clinical trial.
Morris, Michael J.
Higano, Celestia S.
Scher, Howard I.
Sweeney, Christopher
Antonarakis, Emmanuel S.
Shevrin, Daniel H.
Ryan, Charles J.
Loriot, Yohann
Fizazi, Karim
Pandit-Taskar, Neeta
Garcia-Vargas, Jose E.
Lyseng, Kari
Bloma, Marianne
Carrasquillo, Jorge A.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 →